Diabetes Mellitus, Type 2
Conditions
Brief summary
The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels. Participants will get Rybelsus® as prescribed to them by the study doctor. The study will last for about 8-10 months. Participants will be asked to complete a questionnaire about how they take their Rybelsus® tablets. Participants will complete this questionnaire during their normally scheduled visit with the study doctor.
Interventions
DRUGOral Semaglutide
Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
Sponsors
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol) * Diagnosed with type 2 diabetes mellitus * The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study * Male or female, age above or equal to 18 years at the time of signing informed consent * Available HbA1c value less than or equal to 90 days prior to the 'Informed Consent and Treatment Initiation visit' (V1) or HbA1c measurement taken in relation with the 'Informed Consent and Treatment Initiation visit'(V1) if in line with local clinical practice * Treatment naïve to injectable glucose-lowering drug(s). An exception is short-term insulin treatment for acute illness for a total of less than or equal to 14 days
Exclusion criteria
* Previous participation in this study. Participation is defined as having given informed consent in this study * Treatment with any investigational drug within 30 days prior to enrolment into the study * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Glycated haemoglobin (HbA1c ) | From baseline (week 0) to End of Study visit (V3) (week 34-44) | percent-points |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Relative change in body weight | From baseline (week 0) to End of Study visit (V3) (week 34-44) | percent |
| Absolute change in body weight | From baseline (week 0) to End of Study visit (V3) (week 34-44) | Kilogram (Kg) |
| HbA1c <7% (Yes/No) | End of Study visit (V3) (week 34-44) | Percentage of patients achieving or not achieving the target value |
| HbA1c reduction >=1%-points and body weight reduction of >=5% (Yes/No) | From baseline (week 0) to End of Study visit (V3) (week 34-44) | Percentage of patients achieving or not achieving the reduction |
| HbA1c reduction >=1%-points and body weight reduction of >=3% (Yes/No) | From baseline (week 0) to End of Study visit (V3) (week 34-44) | Percentage of patients achieving or not achieving the reduction |
Countries
Switzerland
Outcome results
None listed